# A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury

> **NCT04335578** · PHASE1,PHASE2 · TERMINATED · sponsor: **UCB Biopharma SRL** · enrollment: 3 (actual)

## Conditions studied

- Chronic Allograft Injury

## Interventions

- **DRUG:** Zampilimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04335578
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-21
- **Primary completion:** 2022-05-04
- **Final completion:** 2022-05-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Recruitment challenges
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04335578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04335578, "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04335578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*